The Drug-Induced Respiratory Disease Website
Typically acute. Can be fulminate/fulminant and fatal (PMID 30242316). General review at PMID 28540649. Recent addition to the lst of causal drugs include immune checkpoint inhibitors (PMID 28833116, 29801747)
Publications
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.
Investigational new drugs 2024 Feb;42;116-126 — 2024 Feb — 116-126
Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Internal medicine journal 2020 Aug;50;1003-1006 — 2020 Aug — 1003-1006
Yamaguchi S, Morimoto R, Okumura T, Yamashita Y, Haga T, Kuwayama T, Yokoi T, Hiraiwa H, Kondo T, Sugiura Y, Watanabe N, Kano N, Kohno K, Fukaya K, Sawamura A, Yokota K, Ishii H, Nakaguro M, Akiyama M, Murohara T
Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
The Canadian journal of cardiology 2018 06;34;812.e1-812.e3 — 2018 06 — 812.e1-812.e3
Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM
Smoldering myocarditis following immune checkpoint blockade.
Journal for immunotherapy of cancer 2017 11 21;5;91 — 2017 11 21 — 91
Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.
Journal of forensic sciences 2018 May;63;954-957 — 2018 May — 954-957
Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Neurology 2017 Sep 12;89;1127-1134 — 2017 Sep 12 — 1127-1134
Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
Lung cancer (Amsterdam, Netherlands) 2016 09;99;117-9 — 2016 09 — 117-9
Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.
BMJ case reports 2016 Jul 20;2016; — 2016 Jul 20